$1,318.00
This Market Spotlight report covers the Basal Cell Carcinoma market, comprising key marketed and pipeline drugs, epidemiology, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Basal Cell Carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Electrodesiccation and curettage (ED&C)
8 Mohs micrographic surgery
8 Excisional surgery
8 Radiation therapy
9 Cryosurgery
9 Photodynamic therapy (PDT)
9 Laser surgery
9 Pharmacological therapies
11 EPIDEMIOLOGY
11 Recent incidence studies
12 MARKETED DRUGS
15 PIPELINE DRUGS
20 KEY UPCOMING EVENTS
21 PROBABILITY OF SUCCESS
22 LICENSING AND ASSET ACQUISITION DEALS
22 Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses
22 Evotec Pairs Up With Almirall On Severe Skin Disease
23 REVENUE OPPORTUNITY
24 CLINICAL TRIAL LANDSCAPE
25 Sponsors by status
26 Sponsors by phase
28 BIBLIOGRAPHY
29 APPENDIX
LIST OF FIGURES
15 Figure 1: Overview of pipeline drugs for basal cell carcinoma in the US
15 Figure 2: Pipeline drugs for basal cell carcinoma, by company
16 Figure 3: Pipeline drugs for basal cell carcinoma, by drug type
16 Figure 4: Pipeline drugs for basal cell carcinoma, by classification
20 Figure 5: Key upcoming events in basal cell carcinoma
21 Figure 6: Probability of success in the solid tumors pipeline
24 Figure 7: Clinical trials in basal cell carcinoma
24 Figure 8: Top 10 drugs for clinical trials in basal cell carcinoma
25 Figure 9: Top 10 companies for clinical trials in basal cell carcinoma
25 Figure 10: Trial locations in basal cell carcinoma
26 Figure 11: Basal cell carcinoma trials status
27 Figure 12: Basal cell carcinoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Marketed drugs for basal cell carcinoma
17 Table 2: Pipeline drugs for basal cell carcinoma in the US
23 Table 3: Historical global sales, by drug ($m), 2017–21
23 Table 4: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!